U.S. Allergy Immunotherapy Market Size & Outlook, 2019-2027
U.S. allergy immunotherapy market, 2016-2027 (US$M)
Related Markets
U.S. allergy immunotherapy market highlights
- The U.S. allergy immunotherapy market generated a revenue of USD 278.0 million in 2019 and is expected to reach USD 631.7 million by 2027.
- The U.S. market is expected to grow at a CAGR of 10.8% from 2020 to 2027.
- In terms of segment, subcutaneous immunotherapy was the largest revenue generating treatment type in 2019.
- Sublingual immunotherapy is the most lucrative treatment type segment registering the fastest growth during the forecast period.
Allergy immunotherapy market data book summary
| Market revenue in 2019 | USD 278.0 million |
| Market revenue in 2027 | USD 631.7 million |
| Growth rate | 10.8% (CAGR from 2019 to 2027) |
| Largest segment | Subcutaneous immunotherapy |
| Fastest growing segment | Sublingual immunotherapy |
| Historical data | 2016 - 2018 |
| Base year | 2019 |
| Forecast period | 2020 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Subcutaneous immunotherapy, Sublingual immunotherapy |
| Key market players worldwide | Merck KGaA, Allergy Therapeutics PLC, DBV Technologies SA ADR, ASIT biotech, Circassia, Mylan, DMK Pharmaceuticals Corp, Alk-Abello A/S Class B, Desentum, HAL Allergy Group, HollisterStier Allergy, Stallergenes Greer |
Other key industry trends
- In terms of revenue, U.S. accounted for 17.4% of the global allergy immunotherapy market in 2019.
- Country-wise, Germany is expected to lead the global market in terms of revenue in 2027.
- In North America, U.S. allergy immunotherapy market is projected to lead the regional market in terms of revenue in 2027.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 631.7 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Allergy Immunotherapy Market Scope
Allergy Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. allergy immunotherapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to allergy immunotherapy market will help companies and investors design strategic landscapes.
Subcutaneous immunotherapy was the largest segment with a revenue share of 83.99% in 2019. Horizon Databook has segmented the U.S. allergy immunotherapy market based on subcutaneous immunotherapy, sublingual immunotherapy covering the revenue growth of each sub-segment from 2016 to 2027.
Key players are involved in extensive R&D for the production of immunotherapy solutions for food allergy. For instance, Aimmune Therapeutics is developing an investigational biologic immunotherapy drug, AR101, for peanut allergy.
The product has been studied in more than 1,000 participants in clinical trials. In addition, FDA is reviewing the product at present and has accepted Biologics License Application (BLA) for the same in 2019.
The company has also submitted Marketing Authorization Application (MAA) for its AR101 product to European Medicines Agency (EMA). Similarly, Sanofi Pharmaceuticals sponsored a 2018 clinical study to evaluate the tolerability and safety of its investigational product SAR439794 designed for sublingual immunotherapy for peanut allergies.
Reasons to subscribe to U.S. allergy immunotherapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. allergy immunotherapy market databook
-
Our clientele includes a mix of allergy immunotherapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. allergy immunotherapy market, including forecasts for subscribers. This country databook contains high-level insights into U.S. allergy immunotherapy market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. allergy immunotherapy market size, by treatment type, 2016-2027 (US$M)
U.S. Allergy Immunotherapy Market Share, 2019 & 2027 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
